Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that affects a variety of organ systems. Anti-dsDNA Abs and complement factors have been used as indicators of lupus activity for more than 50 years. A novel indicator of activation in SLE is reported in this paper. Anti-collagen type II (CII) Ab was obviously elevated in patients with SLE compared to those patients with ankylosing spondylitis (AS) and healthy controls (HCs). Anti-CII-Ab-positive patients with SLE showed significantly higher levels of serum IgG and higher titers of ANA but lower levels of C3 and C4 than controls. A positive correlation was demonstrated between anti-CII Ab and serum IgG in SLE patients (r = 0.50, p < 0.0001). The negative correlations of anti-CII Ab with C3 and C4 were observed in SLE patients (r = –0.36, p = 0.0013; r = –0.37, p = 0.0006, respectively). The reduced anti-CII Ab level was accompanied by decreased level of serum IgG and increased levels of C3 and C4 after regular treatment. Therefore, anti-CII Ab could be a novel indicator for monitoring activity of SLE.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358: 929–939.
2.
MoscaMTaniCAringerM. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis2010; 69: 1269–1274.
3.
HahnBH. Antibodies to DNA. N Engl J Med1998; 338: 1359–1368.
GioudMMeghlaouiACostaOMonierJC. Antibodies to native type I and II collagens detected by an enzyme linked immunosorbent assay (ELISA) in rheumatoid arthritis and systemic lupus erythematosus. Coll Relat Res1982; 2: 557–564.
6.
TeratoKShimozuruYKatyamaK. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum1990; 33: 1493–1500.
7.
CookADRowleyMJMackayIRGoughAEmeryP. Antibodies to type II collagen in early rheumatoid arthritis—correlation with disease progression. Arthritis Rheum1996; 39: 1720–1727.
8.
KimHYKimWUChoML. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255–274) in patients with rheumatoid arthritis. Arthritis Rheum1999; 42: 2085–2093.
9.
MullazehiMWickMCKlareskogLvan VollenhovenRRönnelidJ. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res Ther2012; 14: R100–R100.
10.
KimWUYooWHParkW. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol2000; 27: 575–581.
EsdaileJMDanoffDRosenthallLGutkowskiA. Deforming arthritis in systemic lupus erythematosus. Ann Rheum Dis1981; 40: 124–126.
13.
Alarcόn-SegoviaDAbud-MendozaCDiaz-JouanenEIglesiasADe los ReyesVHernández-OrtizJ. Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol1988; 15: 65–69.
14.
van VugtRMDerksenRHKaterLBijlsmaJW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis1998; 57: 540–544.
15.
PriceJVHaddonDJKemmerD. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest2013; 123: 5135–5145.
16.
MeghlaouiAHerbageDHucAMonierJC. Detection of anti-collagen type I and II antibodies by an immunoenzymatic technique (ELISA): Results in rheumatoid arthritis, systemic lupus erythematosus and leprosy [article in French]. Ann Immunol (Paris)1981; 132C: 287–305.
17.
FukasawaYKanoS. Anti-type II collagen antibodies in collagen disease [article in Japanese]. Rinsho Byori1993; 41: 876–881.
18.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
19.
AletahaDNeogiTSilmanAJ. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum2010; 62: 2569–2581.
20.
RudwaleitMvan der HeijdeDLandewéR. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis2009; 68: 777–783.
21.
MullazehiMMathssonLLampaJRönnelidJ. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis2007; 66: 537–541.
22.
PisetskyDS. Anti-DNA and autoantibodies. Curr Opin Rheumatol2000; 12: 364–368.
23.
VillarrealGMDrenkardCVillaAR. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. Lupus1997; 6: 425–435.
24.
ValentijnRMvan OverhagenHHazevoetHM. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum1985; 28: 904–913.
25.
LloydWSchurP. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore)1981; 60: 208–217.
26.
AggarwalRSequeiraWKokebieR. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken)2011; 63: 891–898.
27.
ParkYBLeeSKKimDSLeeJLeeCHSongCH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol1998; 16: 283–288.
